KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Other Accumulated Expenses (2016 - 2023)

Historic Other Accumulated Expenses for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to -$907.9 million.

  • Gsk's Other Accumulated Expenses fell 4202.6% to -$907.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$907.9 million, marking a year-over-year decrease of 4202.6%. This contributed to the annual value of -$752.9 million for FY2024, which is 2228.58% down from last year.
  • As of Q3 2025, Gsk's Other Accumulated Expenses stood at -$907.9 million, which was down 4202.6% from -$767.1 million recorded in Q2 2025.
  • Gsk's Other Accumulated Expenses' 5-year high stood at -$40.3 million during Q1 2022, with a 5-year trough of -$947.1 million in Q3 2021.
  • Moreover, its 5-year median value for Other Accumulated Expenses was -$699.0 million (2025), whereas its average is -$707.0 million.
  • As far as peak fluctuations go, Gsk's Other Accumulated Expenses skyrocketed by 9565.58% in 2022, and later tumbled by 152148.19% in 2023.
  • Over the past 5 years, Gsk's Other Accumulated Expenses (Quarter) stood at -$849.2 million in 2021, then rose by 26.52% to -$624.0 million in 2022, then grew by 1.54% to -$614.4 million in 2023, then dropped by 23.05% to -$756.0 million in 2024, then fell by 20.1% to -$907.9 million in 2025.
  • Its last three reported values are -$907.9 million in Q3 2025, -$767.1 million for Q2 2025, and -$699.0 million during Q1 2025.